4
Changes in Ownership
Aclaris Therapeutics, Inc. Filed Acc 0001209191-23-016065
Chief Scientific Officer sold 30,837 shares at an average $12.51 ($385,639)
- Chief Scientific Officer acquired 87,175 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Monahan Joseph Chief Scientific Officer | 2023-03-01 | Option exercise | +13,750 | 105,136 | D | ||
| Monahan Joseph Chief Scientific Officer | 2023-03-01 | Option exercise | +50,000 | 155,136 | D | ||
| Monahan Joseph Chief Scientific Officer | 2023-03-01 | Option exercise | +10,925 | 166,061 | D | ||
| Monahan Joseph Chief Scientific Officer | 2023-03-02 | Sale | −14,800 | $12.37 | $183,024 | 151,261 | D |
| Monahan Joseph Chief Scientific Officer | 2023-03-02 | Option exercise | +12,500 | 163,761 | D | ||
| Monahan Joseph Chief Scientific Officer | 2023-03-03 | Sale | −16,037 | $12.63 | $202,615 | 147,724 | D |
| Derivatives | |||||||
| Monahan Joseph Chief Scientific Officer | 2023-03-01 | Option exercise · Restricted Stock Units | −13,750 | 0 | D | ||
| Monahan Joseph Chief Scientific Officer | 2023-03-01 | Option exercise · Restricted Stock Units | −50,000 | 100,000 | D | ||
| Monahan Joseph Chief Scientific Officer | 2023-03-01 | Option exercise · Restricted Stock Units | −10,925 | 32,775 | D | ||
| Monahan Joseph Chief Scientific Officer | 2023-03-02 | Option exercise · Restricted Stock Units | −12,500 | 12,500 | D | ||
| Open-market sales · 30,837 sh · avg $12.51 · $385,639 | |||||||
Loading xslF345X03/doc4.xml…